The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

Summary

Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes. The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.

Timeline

Start

2015-01

Primary completion

2016-01

Completion

2017-01

Outcome

Outcome not reported

Stopped: “the manufacturer decided to halt manufacturing the vaccine”

Drugs

Indications